Compugen grants 70,000 options to COO Ferre

Compugen Ltd granted Chief Operating Officer Pierre Ferre 70,000 share options over ordinary shares at an exercise price of $4.00 per share, expiring on July 29, 2036.

Accepted by SEC EDGAR 07/30/2026 - 04:07 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Compugen Ltd granted Chief Operating Officer Pierre Ferre 70,000 share options over ordinary shares at an exercise price of $4.00 per share, expiring on July 29, 2036. The option vests 25% on September 30, 2027, with the remainder vesting in 12 equal quarterly installments, subject to his continued service.

Insider Trade Summary

Grant/Award: 70,000 shares

Grant/Award 1 txn

Insider Ferre Pierre

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Share Option (right to buy) F1	70,000	$0.00	$0.00

Holdings After Transaction: Share Option (right to buy) — 70,000 contracts (Direct)

Footnotes (1)

1. F1. This option vests 25% on September 30, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

Key Figures

Options granted: 70,000 share options Exercise price: $4.0000 per share Expiration date: 2036-07-29 +2 more

5 metrics

Options granted 70,000 share options Grant to Chief Operating Officer Pierre Ferre on 2026-07-29

Exercise price $4.0000 per share Exercise price of the granted share options

Expiration date 2036-07-29 Expiration of Ferre’s share option award

Initial vesting 25% on September 30, 2027 Portion of the options vesting on the first vesting date

Remaining vesting installments 12 equal quarterly installments Balance of the options vests quarterly after initial vesting, subject to continued service

Key Terms

Share Option (right to buy), exercise price, vests, quarterly installments

4 terms

Share Option (right to buy) financial

"Security title reported as Share Option (right to buy)"

exercise price financial

"Options carry an exercise price of $4.0000 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests financial

"This option vests 25% on September 30, 2027"

quarterly installments financial

"The remainder vests in 12 equal quarterly installments thereafter"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock option grant did COMPUGEN (CGEN) report for Pierre Ferre?

Compugen granted Chief Operating Officer Pierre Ferre 70,000 share options over ordinary shares at an exercise price of $4.00 per share. The options were awarded on July 29, 2026 and represent a new equity-based compensation grant.

What is the exercise price of Pierre Ferre’s new COMPUGEN (CGEN) options?

The granted share options carry an exercise price of $4.00 per share. This means Ferre may purchase up to 70,000 ordinary shares at $4.00 each once the options have vested and before they expire on July 29, 2036.

When do Pierre Ferre’s COMPUGEN (CGEN) options start vesting?

The option grant begins vesting on September 30, 2027, when 25% of the award vests. The remaining options then vest in 12 equal quarterly installments, so the position builds gradually over several years, assuming his continued service with Compugen.

How long will Pierre Ferre’s COMPUGEN (CGEN) stock options remain exercisable?

The share options granted to Pierre Ferre expire on July 29, 2036. He may exercise vested portions any time after they vest and before this expiration date, subject to the company’s equity plan terms and applicable securities-law and trading restrictions.

What conditions apply to the vesting of COMPUGEN (CGEN) options granted to Pierre Ferre?

Vesting of the award is subject to Pierre Ferre’s continued service with Compugen. Twenty-five percent vests on September 30, 2027, and the remaining 75% vests in 12 equal quarterly installments thereafter, so leaving the company early could limit the vested portion.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ferre Pierre

(Last) (First) (Middle)

C/O COMPUGEN LTD.

26 HAROKMIM STREET

(Street)

HOLON 5885849

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
COMPUGEN LTD [ CGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol
[CGEN]

3. Date of Earliest Transaction (Month/Day/Year)
07/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	$4	07/29/2026		A		70,000		(1)	07/29/2036	Ordinary Shares	70,000	$0	70,000	D

Explanation of Responses:

1. This option vests 25% on September 30, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

	/s/ Pierre Ferre	07/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)